Reno-protective effects of Phosphodiesterase 5 inhibitors
- 22 March 2021
- journal article
- review article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 25 (6) , 585-597
Abstract
The kidneys are vital organs that play an important role in removing waste materials from the blood, electrolyte balance, blood pressure regulation, and red blood cell genesis. Kidney disease can be caused by various factors, including diabetes, ischemia/reperfusion injury, and nephrotoxic agents. Inflammation and oxidative stress play a key role in the progression and pathogenesis of kidney diseases. Acute kidney injury (AKI) and chronic kidney disease (CKD) are important health problems worldwide, as they are associated with a long-term hospital stay, and increased morbidity and mortality in high-risk patients. Current standard therapeutic options are not sufficient to delay or stop the loss of kidney function. Therefore, it is necessary to develop new therapeutic options. Phosphodiesterase 5 inhibitors (PDE5Is) are a currently available class of drugs that are used to treat erectile dysfunction and pulmonary hypertension in humans. However, recent evidence suggests that PDE5Is have beneficial renoprotective effects via a variety of mechanisms. In this review, the benefits of PDE5 inhibitors in clinical conditions associated with kidney disease, such as diabetic nephropathy, ischemia–reperfusion injury, and acute and chronic kidney injury, are summarized.Keywords
This publication has 75 references indexed in Scilit:
- The renoprotective effect of cGMP phosphodiesterase inhibitor and nitroprusside in a rat model of cyclosporin A-induced nephrotoxicityClinical Nephrology, 2013
- Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological studyClinical and Experimental Immunology, 2011
- Off the Beaten Renin–Angiotensin–Aldosterone System Pathway: New Perspectives on Antiproteinuric TherapyAdvances in Chronic Kidney Disease, 2011
- Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non‐insulin‐dependent Otsuka Long‐Evans Tokushima Fatty ratsBritish Journal of Pharmacology, 2011
- Systemic and metabolic effects of PDE5-inhibitor drugsWorld Journal of Diabetes, 2010
- Oxidative Stress as a Mediator of Cardiovascular DiseaseOxidative Medicine and Cellular Longevity, 2009
- Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to ANP in the pregnant ratAmerican Journal of Physiology-Renal Physiology, 2007
- Maximizing the Renal Cyclic 3′-5′-Guanosine Monophosphate System with Type V Phosphodiesterase Inhibition and Exogenous Natriuretic PeptideJournal of the American Society of Nephrology, 2006
- The clinical and renal consequences of contrast-induced nephropathyNephrology Dialysis Transplantation, 2006
- Animal Model of Adenine-Induced Chronic Renal Failure in RatsNephron, 1986